What SEC filings does enVVeno Medical Corporation submit to the SEC?

enVVeno Medical Corporation (NVNO) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about NVNO?

A Form 4 for NVNO discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the source-reported date, number of shares, price, and updated ownership. These facts do not establish motive or predict future returns.

How do I interpret an 8-K filing from enVVeno Medical Corporation?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for NVNO?

The 10-K is enVVeno Medical Corporation's annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all NVNO SEC filings directly on EDGAR?

You can view all historical enVVeno Medical Corporation filings on the SEC EDGAR company page for NVNO. Each filing card on this page links directly to the original SEC document.

How often does enVVeno Medical Corporation file with the SEC?

enVVeno Medical Corporation files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling NVNO shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

NVNO SEC Filing News — enVVeno Medical Corporation

Latest SEC filings for enVVeno Medical Corporation (NVNO) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-09-14.

enVVeno Medical Corporation, a medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease in the United States. The company's lead product is the VenoValve, a surgical replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The company …

Sector: Healthcare Industry: Medical Devices Market Cap: $5.2M CIK: 1661053

Total Filings

Bullish Classifications

Bearish Classifications

Insider Transactions

Material Events (8-K)

Periodic Reports

Rule-based classifications for NVNO currently lean bearish. Of the 20 filing records displayed, 3 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 0 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.

NVNO Filing Activity Snapshot 2025-12-15 — 2026-09-14

Insider Transactions (Form 4)

0 buys vs 3 sells

Net insider selling in this period — insiders sell for many reasons beyond conviction.

Largest Form 144 Filing

$1.6K

Duhay Francis (Director) · 2026-03-13

140 shares · Form 4

Form 144 Notices

Proposed insider sales filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.

Insider Transactions 10 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 10 filings in this group are Form 4s for enVVeno Medical Corporation.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 10 insider filings shown, the breakdown is 4 compensation award, 3 other reported transaction and 3 open-market sale. 3 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Compensation award ×4: Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.
Other reported transaction ×3: The filing reports a transaction type that does not map to a routine purchase, sale, award or withholding.
Open-market sale ×3: The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Form 4 Open-market sale Insider Selling 2026-09-14

NVNO insider Duhay Francis (Director) sold 11 shares (~$123.31)

Duhay Francis, listed as Director at enVVeno Medical Corp, reported an open-market sale of 11 NVNO shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	11	$11.21	$123.31

Filing: Form 4 (Insider Transaction) Insider: Duhay Francis (Director) Shares: 11 Est. Value: $123.31

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-06-12

NVNO insider Duhay Francis (Director) sold 140 shares (~$1.4K)

Duhay Francis, listed as Director at enVVeno Medical Corp, reported an open-market sale of 140 NVNO shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	140	$10.30	$1.4K

Filing: Form 4 (Insider Transaction) Insider: Duhay Francis (Director) Shares: 140 Est. Value: $1.4K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-03-13

NVNO insider Duhay Francis (Director) sold 140 shares (~$1.6K)

Duhay Francis, listed as Director at enVVeno Medical Corp, reported an open-market sale of 140 NVNO shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	140	$11.52	$1.6K

Filing: Form 4 (Insider Transaction) Insider: Duhay Francis (Director) Shares: 140 Est. Value: $1.6K

View on SEC EDGAR → Open Filing Document →

Form 4 Other reported transaction Tax / Compensation Filing 2025-12-18

NVNO insider Form 4 filed for equity award, exercise, or tax withholding

BERMAN ROBERT ANDREW (Director, Chief Executive Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The filing reports a transaction type that does not map to a routine purchase, sale, award or withholding.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`J`	Other transaction derivative · Restricted Stock Units	200,000	—	—

Filing: Form 4 (Insider Transaction) Insider: BERMAN ROBERT ANDREW (Director, Chief Executive Officer)

View on SEC EDGAR → Open Filing Document →

Form 4 Other reported transaction Tax / Compensation Filing 2025-12-18

NVNO insider Form 4 filed for equity award, exercise, or tax withholding

Alavi Hamed (Chief Technology Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The filing reports a transaction type that does not map to a routine purchase, sale, award or withholding.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`J`	Other transaction derivative · Restricted Stock Units	50,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Alavi Hamed (Chief Technology Officer)

View on SEC EDGAR → Open Filing Document →

Form 4 Other reported transaction Tax / Compensation Filing 2025-12-18

NVNO insider Form 4 filed for equity award, exercise, or tax withholding

Glickman Marc H. (SVP & Chief Medical Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The filing reports a transaction type that does not map to a routine purchase, sale, award or withholding.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`J`	Other transaction derivative · Restricted Stock Units	100,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Glickman Marc H. (SVP & Chief Medical Officer)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2025-12-15

NVNO insider Form 4 filed for equity award, exercise, or tax withholding

Duhay Francis (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Options	135,883	—	—

Filing: Form 4 (Insider Transaction) Insider: Duhay Francis (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2025-12-15

NVNO insider Form 4 filed for equity award, exercise, or tax withholding

Gray Robert (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Options	135,883	—	—

Filing: Form 4 (Insider Transaction) Insider: Gray Robert (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2025-12-15

NVNO insider Form 4 filed for equity award, exercise, or tax withholding

Jenusaitis Matthew (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Options	135,883	—	—

Filing: Form 4 (Insider Transaction) Insider: Jenusaitis Matthew (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2025-12-15

NVNO insider Form 4 filed for equity award, exercise, or tax withholding

Shrivastava Sanjay (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Options	135,883	—	—

Filing: Form 4 (Insider Transaction) Insider: Shrivastava Sanjay (Director)

View on SEC EDGAR → Open Filing Document →

Proposed Insider Sales 3 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. enVVeno Medical Corporation has 3 such notices in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Proposed Insider Sale 2026-09-11

NVNO Form 144 filed for proposed insider sale

An insider at enVVeno Medical Corp filed a Form 144 notifying the SEC of an intent to sell shares. Form 144 is a proposed sale notice rather than confirmation that a sale already happened.

Filing: Form 144 (Proposed Sale Notice)

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-06-11

NVNO Form 144 filed for proposed insider sale

An insider at enVVeno Medical Corp filed a Form 144 notifying the SEC of an intent to sell shares. Form 144 is a proposed sale notice rather than confirmation that a sale already happened.

Filing: Form 144 (Proposed Sale Notice)

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-03-12

NVNO Form 144 filed for proposed insider sale

An insider at enVVeno Medical Corp filed a Form 144 notifying the SEC of an intent to sell shares. Form 144 is a proposed sale notice rather than confirmation that a sale already happened.

Filing: Form 144 (Proposed Sale Notice)

View on SEC EDGAR → Open Filing Document →

Material Events 4 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 4 in this period for enVVeno Medical Corporation. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-07-14

NVNO filed 8-K — material company event

enVVeno Medical Corp filed an 8-K with the SEC reporting a material event. Read the SEC filing for the full details.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-04-29

NVNO filed 8-K — material company event

enVVeno Medical Corp filed an 8-K with the SEC reporting a material event. Read the SEC filing for the full details.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-02-04

NVNO filed 8-K — material company event

enVVeno Medical Corp filed an 8-K with the SEC reporting a material event. Read the SEC filing for the full details.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-01-20

NVNO filed 8-K — material company event

enVVeno Medical Corp filed an 8-K with the SEC reporting a material event. Read the SEC filing for the full details.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Periodic Reports 3 · Forms 10-K and 10-Q

The periodic reports are where the audited and reviewed financial statements live. This period contains 1 annual report (10-K) and 2 quarterly reports (10-Q) for enVVeno Medical Corporation.

The two are not equivalent in weight. A 10-K is audited by an external firm and includes the full risk factor disclosure, business description and management discussion; a 10-Q is unaudited, reviewed rather than examined, and much shorter. When a figure in a quarterly report is later revised, the annual report is usually where the correction appears.

An amended report — 10-K/A or 10-Q/A — restates or corrects something in the original filing, and is worth reading against the version it replaces.

Form 10-Q Quarterly Report 2026-07-30

NVNO filed Quarterly Report (10-Q)

enVVeno Medical Corp filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)

View on SEC EDGAR → Open Filing Document →

Form 10-Q Quarterly Report 2026-05-06

NVNO filed Quarterly Report (10-Q)

enVVeno Medical Corp filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)

View on SEC EDGAR → Open Filing Document →

Form 10-K Annual Report 2026-03-26

NVNO filed Annual Report (10-K)

enVVeno Medical Corp filed its annual report with the SEC. This report includes audited financial statements, business overview, risk factors, and management discussion.

Filing: 10-K (Annual Report)

View on SEC EDGAR → Open Filing Document →

How we classify enVVeno Medical Corporation's filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on NVNO. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — NVNO SEC Filings

More Tools for NVNO

NVNO Full Stock Analysis NVNO Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper NVNO analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the NVNO stock analysis page.

NVNO Full Analysis

Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.

Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer